✦ LIBER ✦

Update on the management of hepatitis C in liver transplant recipients

✍ Scribed by David A. Bobak; Gopal Yadavalli

Book ID: 107542200
Publisher: Springer
Year: 2002
Tongue: English
Weight: 364 KB
Volume: 4
Category: Article
ISSN: 1523-3847
DOI: 10.1007/s11908-002-0049-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of hepatitis C in liver transp

Treatment of hepatitis C in liver transplant recipients

✍ Fredric D. Gordon; Paul Kwo; Hugo E. Vargas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Recurrent hepatitis C after liver transplantation is a universal phenomenon. Graft reinfection occurs rapidly; once it is established, allograft cirrhosis and decompensation rapidly ensue in many patients. Treatment with pegylated interferon plus ribavirin is the standard of care among nontransplant

Treating hepatitis C infection in liver

Treating hepatitis C infection in liver transplant recipients

✍ Norah A. Terrault; Marina Berenguer 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 1 views

Chronic infection with hepatitis C virus (HCV) is a growing problem worldwide, with up to 300 million individuals infected, and those with chronic infection are at risk for cirrhosis and hepatocellular carcinoma. HCV infection is the most common indication for liver transplantation in the United Sta

Treatment of hepatitis C in the potentia

Treatment of hepatitis C in the potential liver transplant recipient

✍ Hui-Hui Tan; Thomas D. Schiano 📂 Article 📅 2009 🏛 Current Science Inc. 🌐 English ⚖ 333 KB

Treatment of hepatitis C virus in the li

Treatment of hepatitis C virus in the liver transplant recipient

✍ Lafaine Grant; Jeffrey S. Crippin 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 242 KB

Alemtuzumab induction in non-hepatitis C

Alemtuzumab induction in non-hepatitis C positive liver transplant recipients

✍ Josh Levitsky; Kavitha Thudi; Michael G. Ison; Edward Wang; Michael Abecassis 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views

Limited data exist for the use of alemtuzumab (AL) induction in liver transplantation (LT) recipients. We compared the outcomes of hepatitis C virus-negative LT recipients who received AL induction followed by tacrolimus and mycophenolate mofetil without steroids to cohort who received no AL inducti

Rimantadine for treatment of hepatitis C

Rimantadine for treatment of hepatitis C infection in liver transplant recipients

✍ Sherman, Kenneth E. ;Sickler, Joelle ;Aranda-Michel, Jaime ;Weber, Frederick L. 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 61 KB 👁 2 views

Hepatitis C recurrence after liver transplantation is a serious problem, leading to increased graft loss and morbidity in some individuals. Treatment with interferon and other agents is controversial and not highly efficacious. The use of an effective antiviral agent to reduce or eliminate viral bur